Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence
Fabry disease (FD) is a lysosomal disorder caused by mutations in the GLA gene coding for α‑galactosidase A (α‑GalA). These mutations lead to the accumulation of α‑GalA substrates, including globotriaosylceramide (Gb3). As a consequence of lipid storage, Fabry patients can suffer from neuropathic pa...
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Conference item |
| Baskı/Yayın Bilgisi: |
Elsevier
2017
|